Home

Gilead Sciences (GILD)

118.29
+0.08 (0.06%)
NASDAQ · Last Trade: Oct 14th, 12:03 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close118.21
Open117.52
Bid118.26
Ask118.31
Day's Range116.63 - 118.45
52 Week Range84.34 - 121.83
Volume1,662,210
Market Cap148.31B
PE Ratio (TTM)23.56
EPS (TTM)5.0
Dividend & Yield3.160 (2.67%)
1 Month Average Volume7,753,891

Chart

About Gilead Sciences (GILD)

Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale. Read More

News & Press Releases

Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families
Myrtle Beach, SC - October 13, 2025 - Jerry Pinkas, a distinguished real estate broker with over 20 years of experience, has earned the prestigious Certified Probate Specialist (CPS) designation from the Certified Probate Specialist program. This advanced certification enhances his ability to guide families and executors through the complexities of probate real estate transactions with expertise, compassion, and efficiency across the Grand Strand area of South Carolina, including Horry County and communities such as Myrtle Beach, North Myrtle Beach, Carolina Forest, Conway, Little River, Longs, Murrells Inlet, Pawleys Island, Socastee, Surfside Beach, Forestbrook, Mount Gilead, Aynor, Loris, Garden City, and Grande Dunes.
Via Get News · October 13, 2025
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Monthsbenzinga.com
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy.
Via Benzinga · October 13, 2025
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'benzinga.com
On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade.
Via Benzinga · October 13, 2025
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 Congress October 17 – 21.
By Gilead Sciences, Inc. · Via Business Wire · October 13, 2025
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’stocktwits.com
Via Stocktwits · October 12, 2025
3 S&P 500 Stocks We Approach with Caution
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · October 10, 2025
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2025 financial results and provide a business update.
By Gilead Sciences, Inc. · Via Business Wire · October 9, 2025
Breaking Down Gilead Sciences: 6 Analysts Share Their Viewsbenzinga.com
Via Benzinga · October 8, 2025
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hikeinvestors.com
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.
Via Investor's Business Daily · October 8, 2025
Gilead Sciences Inc (NASDAQ:GILD) Presents a Compelling Case for Value Investorschartmill.com
Gilead Sciences (GILD) presents a strong value investing case with a low P/E ratio, high profitability, and solid cash flow, suggesting the stock may be undervalued.
Via Chartmill · October 8, 2025
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Yearsbenzinga.com
Via Benzinga · October 7, 2025
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runwaystocktwits.com
The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.
Via Stocktwits · October 6, 2025
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036benzinga.com
Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036.
Via Benzinga · October 6, 2025
Telecom Stocks Rattled After Verizon Unexpectedly Names Dan Schulman New CEOinvestors.com
The appointment is effective immediately, replacing Hans Vestberg who has led Verizon since 2018.
Via Investor's Business Daily · October 6, 2025
Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jumpinvestors.com
The company is well known for its HIV treatment, Biktarvy. Biktarvy accounted for more than two-thirds of Gilead's HIV June-quarter sales.
Via Investor's Business Daily · October 6, 2025
Discover the top S&P500 movers in Monday's pre-market session.chartmill.com
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Via Chartmill · October 6, 2025
2 Surefire Dividend Stocks to Buy for the Long Haulfool.com
Both have crushed the market in 2025.
Via The Motley Fool · October 4, 2025
Is Gilead Sciences Inc Gaining or Losing Market Support?benzinga.com
Via Benzinga · October 2, 2025
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheapbenzinga.com
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via Benzinga · October 2, 2025
Market Whales and Their Recent Bets on GILD Optionsbenzinga.com
Via Benzinga · October 2, 2025
2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
Via StockStory · October 1, 2025
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by Danish biotech giant Genmab A/S (NASDAQ: GMAB). The all-cash transaction, valued at approximately $8.0 billion, represents
Via MarketMinute · September 29, 2025
U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a spending bill, with crucial negotiations underway to avert what would be the 15th partial federal government shutdown since 1981. This looming
Via MarketMinute · September 29, 2025
3 Unpopular Stocks We Approach with Caution
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Via StockStory · September 29, 2025
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond. The funding, distributed through the Gilead Foundation, will build on the company’s ongoing work to cultivate a robust talent pipeline comprised of students from a broad spectrum of backgrounds and experiences. These donations represent an ongoing commitment to supporting organizations where Gilead colleagues live and work, including a $1 million grant to the Boys and Girls Clubs of America and $500,000 to the San Mateo Foster City Education Foundation to build STEM curriculum.
By Gilead Sciences, Inc. · Via Business Wire · September 25, 2025